Tümör Nekroz Faktörü-Alfa İnhibitörü Kullanırken Sarkoidoz Gelişen Ankilozan Spondilit Olgusu
Öz
Anahtar Kelimeler
Kaynakça
- 1. Kvien TK, Heiberq, Lie E, Kaufman C, Mikkelsen K, Nordvog BY, Rodevand E. A Norvegian DMARD register: prescriptions of DMARDsand biological agent to patients with inflammatory rheumatic diseases. ClinExpRheumatol2005;23:188-94. 2. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard J‐P, Houvenagel E, et al. Sarcoid‐likegranulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48(8):883–6. 3. Cuchacovich R, Hagan J, Khan T, Richert A, Espinoza LR. Tumor necrosis factor‐alpha (TNF‐α)‐blockade‐induced hepatic sarcoidosis in psoriaticarthritis (PsA): case reportandreview of theliterature. ClinRheumatol. 2011;30(1):133–7. 4.Vigne C.,Tebib, J.-G., Pacheco, Y., &Coury, F. (2013). Sarcoidosis: An underestimated and potentially severe side effect of anti-TNF-alpha t h e r a p y . J o i n t B o n e S p i n e , 8 0 ( 1 ) , 1 0 4 – 1 0 7 . doi:10.1016/j.jbspin.2012.05.001 5. Gerriets V, Bansal P, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. 2020 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 29494032. 6.Braun J, Davis J, Dougados M, Sieper J, Vander Linden S, Van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. 7.Borekci S, Atahan E, Demir Yilmaz D, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosisfactor-α treatment.Respiration.2015;90(3):191-198. doi:10.1159/0004346846 8.Wendling D, Nueffer JP. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis. Joint Bone Spine. 2018 Dec;85(6):769. doi: 10.1016/j.jbspin.2018.05.001. Epub 2018 May 19. PMID: 29787812. 9.Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. 10. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis Appearing During Anti‐Tumor NecrosisFactor (alpha) Therapy: A New “Class Effect” Paradoxical Phenomenon. Two Case Reports and LiteratureReview. Semin ArthritisRheum. 2010; 39(4): 313‐9. 11. Cleynen I, Vermeire S. Paradoxicalinflammationinducedby anti‐TNF agents in patientswith IBD. Nat Rev GastroenterolHepatol. 2012;9(9):496– 503. 12. Conrad C, DiDomizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockadeinduces a dysregulatedtype I interferon responswithoutautoimmunity in paradoxicalpsoriasis. NatCommun. 2018;9(1):25. 13.Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27(10):1446–8. 14.Cole P, Rabasseda X. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease. DrugsToday (Barc). 2004;40(4):281–324. 15.Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment withetanercept. AnnRheumDis. 2008; 67(6):896–8. 1 6 . M e n g i G , G ö ğ ü ş F. A R a r e A d v e r s e E ff e c t o f A n t i - TumorNecrosisFactor Alpha Therapy: Sarcoidosis. ArchRheumatol. 2017 Feb 12;32(1):67-70. doi: 10.5606/ArchRheumatol.2017.6055. PMID: 30375550; PMCID: PMC6190941.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Klinik Tıp Bilimleri
Bölüm
Olgu Sunumu
Yazarlar
Muzaffer Şenol
*
Andorra
Neslihan Özçelik
Bu kişi benim
Andorra
Songül Özyurt
Bu kişi benim
Andorra
Bilge Yılmaz Kara
Bu kişi benim
Andorra
Aziz Gümüş
Bu kişi benim
Andorra
Osman Cüre
Bu kişi benim
Andorra
Yayımlanma Tarihi
28 Haziran 2021
Gönderilme Tarihi
25 Şubat 2021
Kabul Tarihi
20 Nisan 2021
Yayımlandığı Sayı
Yıl 2021 Cilt: 1 Sayı: 1
